key: cord-0962256-b62i5rwh
authors: Zheng, Luping; Ma, Yingxin; Chen, Minghai; Wu, Guoqiang; Yan, Chuang; Zhang, Xian-En
title: SARS-CoV-2 spike protein receptor-binding domain N-glycans facilitate viral internalization in respiratory epithelial cells
date: 2021-09-23
journal: Biochem Biophys Res Commun
DOI: 10.1016/j.bbrc.2021.09.053
sha: 7b3147f87d59fb2d860aa3b43062d8beb7c44b79
doc_id: 962256
cord_uid: b62i5rwh

N-glycosylation plays an important role in the pathogenesis of viral infections. However, the role of SARS-CoV-2 RBD N-glycosylation in viral entry remains elusive. In this study, we expressed and purified N331 and N343 N-glycosite mutants of SARS-CoV-2 RBD. We found that de-glycosylation at N331 and N343 drastically reduces the RBD binding to ACE2. More importantly, based on qualitative and quantitative virology research methods, we show that the mutation of RBD N-glycosites interfered with SARS-CoV-2 internalization rather than attachment potentially by decreasing RBD binding to the receptors. Also, the double N-glycosites mutant (N331 + N343) showed significantly increased sensitivity against the designated RBD neutralizing antibodies. Taken together, these results suggest that N-glycosylation of SARS-CoV-2 RBD is not only critical for viral internalization into respiratory epithelial cells but also shields the virus from neutralization. It may provide new insights into the biological process of early-stage SARS-CoV-2 infection with potential therapeutic implications.

Since 2020, the coronavirus disease 2019 (COVID- 19) , a pandemic caused by the novel coronavirus (SARS-CoV-2), has posed an unprecedented threat to the global economy and people's lives. Huge efforts have been made to understand the mechanism of virus infection [1] , develop anti-viral drugs, and vaccines based on the acquired knowledge [2] [3] [4] .

N-glycosylation, the dominant post-translational modification of glycoproteins, had been related to the early infection process, especially for viral entry [5, 6] . About SARS-CoV-2, a site-specific glycan analysis of the recombinant SARS-CoV-2 S revealed two N-glycosylation sites, N331 and N343, on the RBD of the S1 subunit [7] .

Cryo-EM structure-based mapping suggests that these two are in the vicinity of ACE2 receptor binding sites [7] . Moreover, deletion of both N331 and N343 glycosylation drastically reduces viral infectivity, signifying the importance of N-glycosylation at these sites [8] . However, the role of S protein RBD N-glycans in the entry stage, specifically in viral attachment and internalization process, of SARS-CoV-2 infection remains undocumented. Herein, we analyze and discuss the glycopeptide pattern of the recombinant RBD of S1 protein. We examine S1 RBD N-glycosite mutants (N-mut) binding to recombinant ACE2 protein in vitro. Furthermore, pseudovirions carrying RBD N-glycosite mutant S were successfully assembled to investigate the role of RBD N-glycosylation in viral attachment and internalization in respiratory epithelial cells. Also, we examined the change in sensitivity of RBD N-glycosite mutants towards RBD neutralizing antibodies.

Human HEK 293T (ATCC), human pulmonary alveolar epithelial cell (HPAEpic; ScienCell), and human nasal epithelial cell (HNEpc; PromoCell) were maintained in DMEM with 10% fetal bovine serum (FBS) at 37°C and 5% CO2.

SARS-CoV-2 S N-glycosite mutants, prepared by overlap PCR from a SARS-CoV-2 S containing plasmid [9] , were introduced into pcDNA3.1(+) vector.

The SARS-CoV-2 S1 N-glycosite mutants were cloned from SARS-CoV-2 S N-mut with a C-terminal octa-histidine tag. The corresponding primers for plasmid construction are listed in Table S1 . HIV-1 (△env), originated from pNL4-3-KFS and pNL4-3-Luc plasmids, was used to assemble viral particles. Plasmid pcDNA3.1-VSV-G was used to encode Vesicular Stomatitis Virus (VSV) envelope G glycoprotein.

HEK 293 T cells were plated in a 15 cm dish. The cells were transfected with Lipofectamine TM 3000 and cultivated for 48 h. Then, the cells were harvested and resuspended in 2 mL non-denaturing lysis buffer on ice. The lysate was centrifuged at 13000 g for 5 min and the supernatants were mixed with BeyoGold™ His-tag Purification Resin. The recombinant S1 and S1 mut were purified using the His-tag Protein Purification Kit (Bayotime). The eluate was further purified and concentrated J o u r n a l P r e -p r o o f with a 50 kDa centrifugal filter unit (Millipore). Sample purity was also validated by SDS-PAGE.

A 96 wells plate (Acro Biosystems), pre-coated with streptavidin, was normalized to RT. The wells were blocked at 37℃ for 1 h. Then, 0.1 μg biotinylated human ACE2 (Acro Biosystems) was added to each well, and the incubation was performed for 1 h at 37℃. Next, 100 μL of 15.6-500 ng/mL recombinant S1, S1 N-mut and SARS-CoV-2 Spike S2 (negative control) were added to each well with incubation for 1 h at 37℃. These were subsequently treated with SARS-CoV-2 S1 antibody (1:20000) and HRP anti-rabbit IgG at 37℃ for 1 h, respectively. Then, after incubation with tetramethylbenzidine substrate, the reaction was terminated with a stop solution. The absorbance of each well was determined at 450 nm using a microplate reader.

Pseudovirions were produced by co-transfection of HEK 293T cells with 

HPAEpic and HNEpc were plated on glass-bottom dishes before infection with pseudo-VSV-G or pseudo-SARS-CoV-2 S/S N-mut pseudovirus. For viral attachment, the cells in each group were incubated with respective pseudovirion (dose equivalent to 1 μg of p24) at 4℃ for 30 min. Then, a part of the cells was transferred to 37℃ and cultured for 1 h to initiate internalization. The residual pseudovirions on the cell surface were removed by trypsin treatment (0.01%) for 2 min at 37℃.

Fluorescence imaging and quantitative real-time PCR were used for qualitative and quantitative assessment of viral attachment and internalization.

Dio-labeled virions or infected cells were washed with PBS, fixed with freshly prepared 4% paraformaldehyde at RT for 15 min, and permeabilized with 0.1% Triton X-100 for 15 min (for the cells of viral internalization group only). Next, the virions or cells were incubated in 10% FBS, and then incubated with antibody against SARS-CoV-2 S1, VSV-G, followed by secondary antibodies (Alexa Fluor 555-conjugated IgG). The dual-labeled virions were considered as positive and infective pseudovirus. The sample fluorescence of virions or infected cells was monitored with an ECLIPSE Ti confocal system (Nikon, Co.) using a 60 X, 1.4 NA oil immersion objective lens. The images were analyzed with ImageJ software.

Total RNA was extracted from purified virus or harvested cells using RNA extraction kit, respectively. Then, qRT-PCR was performed to determine viral RNA copy numbers using HiScript II U+ One Step qRT-PCR Probe Kit (Vazyme) in the qTOWER 3 Real-Time PCR System (Analytik Jena). Primers and TaqMan probe targeted to the HIV-1 LTR region are shown in Table S2 . Viral RNA copy numbers were calculated using a standard curve generated by serial dilutions of already quantified viral RNA PCR control of pseudo-SARS-CoV-2. The standard sample was absolutely quantified using a droplet digital PCR system (Bio-Rad) with same primers and probe mentioned above.

Recombinant SARS-CoV-2 S1 or S1 N-mut (0.1 μg/well) was coated on a 96-well plate. Then, serially double-fold diluted neutralizing antibody VHH72 (0.625 ng/mL-20 ng/mL, R&D SYSTEMS) [10] or AS35 (0.5 ng/mL-16 ng/mL, Acro Biosystems) [11] was added and incubated at 37℃ for 1 h, followed by addition of HRP conjugated goat anti-human IgG (Abbkine). After completion of the chromogenic reaction, sample OD450 values were recorded.

Next, HNEpc and HPAEpic (100 μL, 1×10 4 cells/well) were seeded into a white bottom 96-well micro-plate. SARS-CoV-2 S/S N-mut and VSV-G pseudovirions, assembled from a pNL4-3-Luc plasmid carrying the luciferase gene, were pre-incubated with 2.5 μg/mL S RBD neutralizing antibody for 1 h on ice. Then, the virus-antibody mixture was added to cells and incubated at 37℃ for 2 h. Viral 

Pseudovirions of SARS-CoV-2 were characterized by negative staining using transmission electron microscopy (TEM). The round-shaped virus particles had an average size of 100 nm (Fig. S2A ). The expression of S and G proteins was confirmed by Western blotting (Fig. S2B-C) . Also, to determine the effect of fluorescent labeling on viral infectivity, the pseudovirions with/without fluorescence were analyzed by luciferase assay at 24 h post infection (hpi). The results showed that DiO-labelling did not impair the virus activity ( Fig. S2D and E) . Pseudo-SARS-CoV-2 S/S N-mut and Pseudo-VSV-G were overlaid onto coverslips and stained for immunofluorescence (IF) with the anti-S ( Fig. S2F; Fig. S3 ) or anti-VSV-G antibodies (Fig. S2G) . The lipid envelope of the pseudo-virus was labeled with DiO. Notably, the majority of it co-localized with the S/S N-mut or VSV-G. This demonstrated the successful J o u r n a l P r e -p r o o f incorporation of SARS-CoV-2 S/S N-mut or VSV-G proteins into the pseudovirions (Fig. S2F, G, and Fig. S3 ).

In HNEpc, after 30 min of co-incubation with pseudo-SARS-CoV-2 S/S N-mut or pseudo-VSV-G (control) at 4℃, all the dual-labeled pseudovirions with or without mutation could attach onto the cell surface with similar efficiency (Fig. 2A, upper panel; Fig. 2B ). This was also evident by the respective RNA copies in the cells (Fig.   2C ). Next, viral internalization was activated by changing the temperature to 37℃.

Interestingly, the internalization efficiency of N331Q+N343Q was dramatically lower than the S-WT, similar to that of pseudo-VSV-G (control). The internalization of the single mutant N331Q or N343Q was also lower, about 23 and 56% of the S-WT, respectively (Fig. 2D) . These findings are in agreement with the results of fluorescence imaging and co-location analysis ( Fig. 2A, lower panel; Fig. 2B ). The attachment and internalization of pseudo-SARS-CoV-2 were also tested in HPAEpic.

Here too, we found similar patterns as in HNEpc (Fig. 3) . The qPCR results indicated that internalization of N331Q, N343Q, and the double mutant decreased by ~37, 57, and 89%, respectively, compared with S-WT (Fig. 3D) . Notably, though the viral attachment onto HNEpc and HPAEpic was of a similar level, the internalization efficiency showed a noticeable decrease in all groups in HPAEpic ( Fig. 2B and Fig.   3B ). The low internalization efficiency of pseudo-VSV-G compared with pseudo-SARS-CoV-2 WT suggest that the entry of the latter was indeed mediated by the S protein interaction with the receptors on these respiratory epithelial cells. Also, J o u r n a l P r e -p r o o f only the pseudovirions dual-labeled with DiO and specific antibodies were considered as positive viral particles.

To further validate these results, we examined the role of total virus surface N-glycans in viral attachment assay in respiratory epithelial cells.

Pseudo-SARS-CoV-2 was treated with peptide-N-glycosidase F (PNGase F) and

de-N-glycosylation was verified by PHA-L lectin blotting (Fig. S4A ). When these were tested in attachment assay, only a very few de-N-glycosylated viral particles could bind to the surface of HNEpc or HPAEpic ( Fig. S4B and C) . Also, the viral RNA copies decreased significantly compared to the control sample ( Fig. S4D and E).

It suggested that the viral surface N-glycans were the predominant factor and indeed responsible for viral attachment and not the RBD N-glycans.

Two commercially available potent SARS-CoV-2 RBD neutralizing antibodies, VHH72 (R&D) and AS35 (Acro Biosystems), were tested against recombinant S1/S1

N-mut by ELISA. The results indicated that compared with S-WT, the S1 binding with double mutations with RBD neutralizing antibodies was much more impacted than that of single mutant (Fig. 4A-B) . Meanwhile, pseudo-SARS-CoV-2 S/S N-mut and pseudo-VSV-G were also tested against these two mAb to test viral infectivity by luciferase assay. VHH72 neutralized pseudo-SARS-CoV-2 S/S N-mut showed decreased viral infectivity in all groups in both HNEpc and HPAEpic (Fig. 4C-F) .

Interestingly, the decrease was most prominent, almost undetectable RLU readings, in 4G and L).

The virus surface N-glycans play a critical role in viral pathogenesis. The heavily glycosylated spike protein of SARS-CoV-2 is vital for interaction between RBD and human cell surface receptor ACE2. We demonstrated that both RBD N-glycosites were glycosylated with complex type N-glycans, lacking high mannose structures. This is consistent with Watanabe et al. and Zhao et al. which also showed that these two RBD N-glycosites were mainly modified as complex N-glycans [7, 12] . It seems that under selective pressure, these complicated and variably modified glycans structures on SARS-CoV-2 RBD could have corresponding biological functions.

Besides, we showed a high abundance of fucosylation and sialylation on N331 and N343, suggesting a potential role of these monosaccharides in viral ligand-receptor J o u r n a l P r e -p r o o f interaction. On the contrary, a high ratio of high-mannose type N-glycans with simpler structure and function than complex-type in the SARS-CoV-2 RBD produced in insect cells [13] explains SARS-CoV-2 preference for higher animals, such as mammals.

It was reported that deletion of both N331 and N343 glycosylation drastically reduces SARS-CoV-2 infectivity [8] . However, the fundamental mechanism remained elusive. In this study, we found that the mutation of RBD N-glycans indeed decreased the interaction between S1 and ACE2 showing their importance in viral entry.

Moreover, we show that the reduction in infectivity mainly affected the viral internalization process rather than attachment to respiratory epithelial cells. Though virus surface N-glycans are critical for attachment [14] and our result also indicated significantly decreased attachment of de-N-glycosylated pseudo-SARS-CoV-2, the mutation of N331 and N343 did not impact the viral attachment. It seems that the remaining S protein N-glycosites or other glycoproteins on the viral membrane are enough for attachment. Also, heparan sulfate, distributed on the surface of virtually all mammalian cells, is considered an important attachment factor for SARS-CoV-2

infection [15] . The decreased viral internalization of de-N-glycosylated N331+N343

can be for two potential reasons. Firstly, the specific monosaccharides at N331 and N343 could be involved in receptor interaction. The N331 and N343 N-glycosites shared similar glycan composition and relative abundance. The 10 most abundant glycans on these two N-glycosites were modified by core or branched-fucosylation.

Also, HexNAc(4)Hex (5) showed that VSV recognizes NMHC-IIA by surface sialic acids and initiates infection [17] . Shajahan et al. revealed that the RBD adjacent highly sialylated glycans at N234

and N282 determine SARS-CoV-2 binding with ACE2 receptors [18] . Very recently, Wang et al. reported that RBDs containing homogeneous N-glycans at N331 and N343 without core fucose and sialic acids did not influence their binding to ACE2 [19] . Thus, the high abundance of fucosylated and sialylated glycans on N-glycosites of SARS-CoV-2 RBD could not be neglected for their role in interaction with host receptors. Given their involvement in protein folding, glycosylation significantly affects the glycoprotein conformation. We speculate that the second reason for impacted viral internalization could be altered SARS-CoV-2 RBD conformation. It seems that the two N-glycosites are critical for suitable binding conformation of the RBD region. Of note, the differential internalization efficiency of pseudo-SARS-CoV-2 in the upper and lower respiratory tract epithelial cells suggests viral tropism towards diverse cells, which may be influenced by the cell surface amount of ACE2. It is reasonable to speculate that SARS-CoV-2 infects nasal J o u r n a l P r e -p r o o f epithelial cells much easier than alveolar epithelial cells because of its aerosol or droplet transmission mode. In addition, we previously showed that the ACE2 expression of HNEpc was indeed higher than that of HPAEpic both at transcription and translation levels [9] .

Though SARS-CoV-2 S glycan shields the immune response [7, 20] , the sensitivity of RBD N-glycans against RBD neutralizing antibodies remains ambiguous. Here, we found that the recombinant S1 N-mut exhibited increased binding with the two neutralizing antibodies targeting RBD epitopes, while the pseudo-SARS-CoV-2 S N-mut showed a lower internalization rate when was blocked with the antibodies. A similar N-glycosite mutation-induced increased antibody neutralization was also reported for HIV-1 gp120 and Nipah virus attachment glycoprotein [21, 22] . The mutants N331 and N343, located in the RBD region, may affect epitope targeting by neutralizing antibodies. The RBD N-glycans likely mask the epitope targeted by the antibody, which is probably an evolutionary mechanism to protect from neutralization and maintain a high affinity for the receptors. Notably, with similar glycan compositions, the binding to the receptors or RBD neutralizing antibodies was different among N331Q, N343Q, and N331Q+N343Q. We speculate that it could be due to the varied spatial location of these two N-glycosites in RBD tertiary structure which influences protein conformation and affinity. Nevertheless, one cannot exclude the possibility that the glycans themselves can be the targets of RBD antibodies. Therefore, the N-glycosites located on the RBD epitope should be 

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Pharmacologic treatments for Coronavirus Disease 2019 (COVID-19): A Review

Immunological considerations for COVID-19 vaccine strategies

A new vaccine to battle Covid-19

Influence of N-linked glycans on intracellular transport of hepatitis C virus E1 chimeric glycoprotein and its role in pseudotype virus infectivity

Role of N-linked glycosylation of the human parainfluenza virus type 3 hemagglutinin-neuraminidase protein

Site-specific glycan analysis of the SARS-CoV-2 spike

The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity

A Dual-fluorescence labeling pseudovirus for real-time imaging of single SARS-CoV-2 entry in respiratory epithelial cells

Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies

Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2

Virus-receptor interactions of glycosylated SARS-CoV-2 spike and human ACE2 receptor

Site-specific N-glycosylation characterization of recombinant SARS-CoV-2 spike proteins

Exploitation of glycosylation in enveloped virus pathobiology

Host and viral determinants for efficient SARS-CoV-2 infection of the human lung

Fucosylated lactosamines participate in adhesion of HIV-1 envelope glycoprotein to dendritic cells

Nonmuscle myosin heavy chain IIA recognizes sialic acids on sialylated RNA viruses to suppress proinflammatory responses via the DAP12-Syk pathway

Deducing the N-and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2

Synthetic homogeneous glycoforms of the SARS-CoV-2 spike receptor-binding domain reveals different binding profiles of monoclonal antibodies

Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition